Literature DB >> 16595616

Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study.

L Tritapepe1, V De Santis, D Vitale, M Santulli, A Morelli, I Nofroni, P E Puddu, M Singer, P Pietropaoli.   

Abstract

BACKGROUND: The calcium sensitizer levosimendan protects against myocardial ischaemia and reperfusion injury in animal models.
METHODS: The present pilot study investigated whether a short infusion before coronary artery bypass grafting (CABG) would protect the myocardium and improve postoperative haemodynamics. Twenty-four patients with stable angina undergoing elective CABG surgery were randomized to receive either placebo or levosimendan (24 microg kg(-1)) infused i.v. over a 10 min period just before placing the patient on cardiopulmonary bypass.
RESULTS: Perioperative haemodynamic variables, concentrations of cardiac troponin I over the 48 h postoperative period, and clinical outcomes were assessed. There were no adverse effects related to levosimendan. Compared with control patients, levosimendan-treated patients had lower postoperative troponin I concentrations (P<0.05) and a higher cardiac index (P<0.05).
CONCLUSION: Patients receiving a short infusion of levosimendan before CABG showed evidence of less myocardial damage, suggestive of a preconditioning effect. Larger outcome studies are thus indicated to confirm benefit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16595616     DOI: 10.1093/bja/ael082

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  21 in total

Review 1.  Pharmacological optimization of tissue perfusion.

Authors:  N Mongardon; A Dyson; M Singer
Journal:  Br J Anaesth       Date:  2009-05-21       Impact factor: 9.166

2.  Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass.

Authors:  Ricardo Levin; Marcela Degrange; Carlos Del Mazo; Eduardo Tanus; Rafael Porcile
Journal:  Exp Clin Cardiol       Date:  2012-09

3.  Preoperative usages of levosimendan in patients undergoing coronary artery bypass grafting.

Authors:  Cuneyt Eris; Senol Yavuz; Faruk Toktas; Tamer Turk; Arif Gucu; Burak Erdolu; M Tugrul Goncu
Journal:  Int J Clin Exp Med       Date:  2014-01-15

Review 4.  [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

Authors:  S Rehberg; C Ertmer; H Van Aken; M Lange; K Bröking; A Morelli; M Westphal
Journal:  Anaesthesist       Date:  2007-01       Impact factor: 1.041

5.  Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial.

Authors:  Zaccaria Ricci; Cristiana Garisto; Isabella Favia; Vincenzo Vitale; Luca Di Chiara; Paola E Cogo
Journal:  Intensive Care Med       Date:  2012-04-18       Impact factor: 17.440

Review 6.  Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.

Authors:  Ibrahim Halil Kurt
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

7.  Heart calcium sensitizer on morbidity and mortality of high-risk surgical patients with MODS: systematic review and meta-analysis.

Authors:  Li Qiao; Chengshan Xu; Xinji Li; Fei Li; Wei Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Prophylactic application of levosimendan in cardiac surgical patients with severe left ventricle dysfunction.

Authors:  Ales Brezina; Hynek Riha; Jan Pirk
Journal:  Exp Clin Cardiol       Date:  2009

Review 10.  Myocardial protection in man--from research concept to clinical practice.

Authors:  Dennis V Cokkinos; Costas Pantos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.